Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05616689 · ClinicalTrials.gov registry record · NA

Bundled Hyperpolypharmacy Deprescribing

A NA study of Polypharmacy, sponsored by Kaiser Permanente.

Completed
Registry status
NA
Development phase
2,471
Enrollment target
1
Study location

NCT05616689: Completed NA study of Polypharmacy, sponsored by Kaiser Permanente.

NCT05616689 is a NA study of Polypharmacy that has completed, run by Kaiser Permanente. The registered enrollment target is 2,471 participants, above the 1,305-participant average among 11 other Polypharmacy trials with a reported enrollment target (89% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05616689, a NA study of Polypharmacy, has completed, sponsored by Kaiser Permanente.

COMPLETED
Registry status
NA
Development phase
2,471 participants
Enrollment target
1
Study location

Study Summary

Older patients using many prescription drugs (hyperpolypharmacy) may be at increased risk of adverse drug effects. This randomized controlled trial tested the effectiveness and safety of a quality intervention intended to reduce hyperpolypharmacy. The study was set at Kaiser Permanente Northern California, an integrated health system with multiple pre-existing deprescribing workflows. Eligible patients were aged ≥76 years using ≥10 prescription medications. The intervention included physician-pharmacist collaborative drug therapy management, standard-of-care practice recommendations, shared decision-making, and deprescribing protocols administered by telephone over multiple cycles for a maximum of 180 days after allocation. A priori primary effectiveness endpoints included change in the number of medications and in the prevalence of geriatric syndrome from 181-365 days after allocation. Second endpoints included utilization and adverse drug withdrawal effects. Information was obtained from the electronic health record.

Primary Outcome

Change in prevalence for any of the following: Falls (hip fracture, lower leg fracture, osteoporosis with fracture, pathologic fracture, osteonecrosis; gait; repeated falls; syncope; tripping; reduced mobility), Cognition (Somnolence; awareness; dizziness; malaise; Urinary incontinence (Unspecified urinary incontinence; retention of urine, unspecified; functional urinary incontinence; stress incontinence ; other specified urinary incontinence) and Pain (Drug induced headache; joint pain; muscle

Conditions Studied

Interventions

  • OTHER Bundled hyperpolypharmacy

Study Locations (1)

California

  • Kaiser Permanente Division of Research - Oakland

Trial Details

FieldValue
Enrollment Target 2,471 participants
Start Date 2020-10-19
Est. Completion 2023-05-24
Phase NA
Kaiser Permanente

294 total trials

What the finished NCT05616689 record still lists

NCT05616689 is an interventional study that assigns participants to a tested intervention. Its 2,471 participants enrollment target places it among the larger protocols in the corpus, above the 1,305-participant average among 11 other Polypharmacy trials with a reported enrollment target (89% higher).

The record links to 1 condition, with Polypharmacy appearing as the primary indexed condition, and to 1 intervention - of which Bundled hyperpolypharmacy is the first listed.

NCT05616689 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05616689 about?

NCT05616689 is a clinical study titled "Bundled Hyperpolypharmacy Deprescribing". Older patients using many prescription drugs (hyperpolypharmacy) may be at increased risk of adverse drug effects. This randomized controlled trial tested the effectiveness and safety of a quality intervention intended to reduce hyperpolypharmacy. The study was set at Kaiser Permanente Northern Cali...

What is the current status of trial NCT05616689?

This trial is currently completed. It is a NA study. The enrollment target is 2,471 participants. The study started on 2020-10-19. Estimated completion is 2023-05-24.

What conditions does trial NCT05616689 study?

This clinical trial studies the following conditions: Polypharmacy.

What interventions are being tested in trial NCT05616689?

The interventions under investigation include: Bundled hyperpolypharmacy (OTHER).

Who is sponsoring clinical trial NCT05616689?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05616689 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Polypharmacy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05616689's enrollment target sits among peer trials

2,471 3rd of 11 higher than 9 of 11 other Polypharmacy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Polypharmacy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06898593 · 2,448 participants · NA

    Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients

  • NCT00001160 · 2,500 participants

    Studies on Tumors of the Thyroid

  • NCT01904188 · 2,500 participants

    Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?

  • NCT02257229 · 2,500 participants

    Prospective Evaluation of Treatment for Clubfoot

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05616689, the US trial registry maintained by the National Library of Medicine. NCT05616689 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.